Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 4, 91-6
eCollection

Reduction in Cancer Risk by Selective and Nonselective cyclooxygenase-2 (COX-2) Inhibitors

Affiliations
Review

Reduction in Cancer Risk by Selective and Nonselective cyclooxygenase-2 (COX-2) Inhibitors

Randall E Harris et al. J Exp Pharmacol.

Abstract

We conducted a series of epidemiologic studies to evaluate the chemopreventive effects of aspirin, ibuprofen, and selective cyxlooxygenase-2 (COX-2) inhibitors (coxibs) against cancers of the breast, colon, prostate, and lung. Composite results across all four cancer sites revealed that regular intake of 325 mg aspirin, 200 mg ibuprofen, or standard dosages of coxibs (200 mg celecoxib or 25 mg rofecoxib) produced risk reductions of 49%, 59%, and 64%, respectively. Use of coxibs for at least 2 years was associated with risk reductions of 71%, 70%, 55%, and 60% for breast cancer, colon cancer, prostate cancer and lung cancer, respectively. Effects of ibuprofen were similar to selective coxibs, and slightly stronger than aspirin. These observed effects are consistent with the relative COX-2 selectivity of ibuprofen, coxibs, and aspirin. Acetaminophen, an analgesic without COX-2 activity, had no effect. Overexpression of COX-2 and increased prostaglandin biosynthesis correlates with carcinogenesis and metastasis at most anatomic sites. These results indicate that regular intake of nonselective or selective COX-2 inhibiting agents protects against the development of major forms of cancer.

Keywords: breast cancer; chemo prevention; colon cancer; inflammation; lung cancer; prostate cancer.

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles

References

    1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):323–235. - PubMed
    1. Harris RE. Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Subcell Biochem. 2007;42:93–126. - PubMed
    1. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89(16):7384–7388. - PMC - PubMed
    1. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 1994;13(3–4):241–256. - PubMed
    1. Herschman HR. Historical aspects of COX-2. In: Harris RE, editor. COX-2 Blockade in Cancer Prevention and Therapy. Totowa, NJ: Humana Press; 2002. pp. 13–34.

LinkOut - more resources

Feedback